Recent News

• 11.18.2025 - Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals
• 11.12.2025 - Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
• 11.10.2025 - Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens
• 10.28.2025 - Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference
• 10.27.2025 - Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update
• 10.09.2025 - Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
• 09.30.2025 - Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection
• 09.03.2025 - Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules
• 08.12.2025 - Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update
• 07.31.2025 - Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split

Recent Filings

• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.10.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 10.20.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 09.22.2025 - 8-K Current report
• 09.19.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.11.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 08.04.2025 - DEF 14A Other definitive proxy statements